Study of Tetrathiomolybdate in Patients With Wilson Disease
Completed
University of Michigan
Phase 3
1994-01-01
OBJECTIVES:
Evaluate the safety and efficacy of ammonium tetrathiomolybdate alone and compared with
trientine therapy as initial treatment in patients with Wilson disease presenting
neurologically.
Study of Tetrathiomolybdate in Patients With Wilson Disease
Completed
National Center for Research Resources (NCRR)
Phase 3
1994-01-01
OBJECTIVES:
Evaluate the safety and efficacy of ammonium tetrathiomolybdate alone and compared with
trientine therapy as initial treatment in patients with Wilson disease presenting
neurologically.
Trientine and Carboplatin in Advanced Malignancies
Completed
M.D. Anderson Cancer Center
Phase 1
2010-07-01
The goal of this clinical research study is to find the highest tolerable dose of the
combination of trientine and carboplatin that can be given to patients with advanced cancer.
The safety of this drug combination will also be studied.
Trientine Hydrochloride for the Prevention of Macular Edema Associated With Pan-retinal Photocoagulation for Severe Non-proliferative and Proliferative Diabetic Retinopathy
Terminated
University of British Columbia
N/A
2010-11-01
To evaluate the effects of Trientine Hydrochloride in prevention of post-laser (pan-retinal
photocoagulation) macular edema in the eyes for subjects with diabetic retinopathy. Trientine
hydrochloride can limit secondary inflammatory damage to retinal vessels following the
administration of pan-retinal photocoagulation therapy for severe non-proliferative diabetic
retinopathy or retinal neovascularization due to diabetic retinopathy, resulting in less
macular edema and improved visual outcomes.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
